Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Chronic recurrent multifocal osteomyelitis Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Chronic recurrent multifocal osteomyelitis indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Familial cold autoinflammatory syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Familial cold autoinflammatory syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Otulipenia Indication Strategy Report 2026: TNF, Trials and Deals
30 July 2026
2026 Otulipenia indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
STING-associated vasculopathy with onset in infancy Indication Strategy Report 2026: STING, Trials and Deals
30 July 2026
2026 STING-associated vasculopathy with onset in infancy indication strategy covering epidemiology, STING biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
COPA syndrome Indication Strategy Report 2026: STING, Trials and Deals
30 July 2026
2026 COPA syndrome indication strategy covering epidemiology, STING biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Deficiency of adenosine deaminase 2 Indication Strategy Report 2026: ADA2, Trials and Deals
30 July 2026
2026 Deficiency of adenosine deaminase 2 indication strategy covering epidemiology, ADA2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Blau syndrome Indication Strategy Report 2026: NOD2, Trials and Deals
30 July 2026
2026 Blau syndrome indication strategy covering epidemiology, NOD2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Majeed syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Majeed syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Cherubism Indication Strategy Report 2026: TNF, Trials and Deals
30 July 2026
2026 Cherubism indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
PASH syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 PASH syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
TNF receptor-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 TNF receptor-associated periodic syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
PAPA syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 PAPA syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.